LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von University of Texas MD Anderson Cancer Center (20)
2024
2023
-
Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer
Cancers, Vol. 15, Núm. 5
-
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935
-
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation
ESMO Open, Vol. 8, Núm. 4
-
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
The Lancet, Vol. 401, Núm. 10378, pp. 733-746
-
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
Cell Reports Medicine, Vol. 4, Núm. 11
2022
-
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Annals of Oncology, Vol. 33, Núm. 5, pp. 466-487
-
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
Nature Medicine, Vol. 28, Núm. 8, pp. 1640-1645
-
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
Annals of Oncology, Vol. 33, Núm. 11, pp. 1168-1178
2021
-
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
ESMO open, Vol. 6, Núm. 3, pp. 100113
-
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
The Lancet Oncology, Vol. 22, Núm. 7, pp. 959-969
2020
-
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy
Journal of Thoracic Oncology, Vol. 15, Núm. 5, pp. 709-740
2017
-
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer
Clinical Lung Cancer
-
First-line nivolumab in stage IV or recurrent non-small-cell lung cancer
New England Journal of Medicine, Vol. 376, Núm. 25, pp. 2415-2426
-
Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer
Lung Cancer, Vol. 112, pp. 181-187
2015
-
A Phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors
Clinical Cancer Research, Vol. 21, Núm. 4, pp. 730-738
2013
-
Epidermal growth factor receptor inhibition in lung cancer: Status 2012
Journal of Thoracic Oncology, Vol. 8, Núm. 3, pp. 373-384
2012
2011
-
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
British Journal of Cancer, Vol. 104, Núm. 1, pp. 68-74
2010
-
Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition
Clinical Cancer Research, Vol. 16, Núm. 18, pp. 4654-4665